keyword
MENU ▼
Read by QxMD icon Read
search

Biomarkers psychiatric disorders

keyword
https://www.readbyqxmd.com/read/28424797/magnetoencephalography-as-a-tool-in-psychiatric-research-current-status-and-perspective
#1
REVIEW
Peter J Uhlhaas, Peter Liddle, David E J Linden, Anna C Nobre, Krish D Singh, Joachim Gross
The application of neuroimaging to provide mechanistic insights into circuit dysfunctions in major psychiatric conditions and the development of biomarkers are core challenges in current psychiatric research. We propose that recent technological and analytic advances in magnetoencephalography (MEG), a technique that allows measurement of neuronal events directly and noninvasively with millisecond resolution, provides novel opportunities to address these fundamental questions. Because of its potential in delineating normal and abnormal brain dynamics, we propose that MEG provides a crucial tool to advance our understanding of pathophysiological mechanisms of major neuropsychiatric conditions, such as schizophrenia, autism spectrum disorders, and the dementias...
April 2017: Biological Psychiatry: Cognitive Neuroscience and Neuroimaging
https://www.readbyqxmd.com/read/28419777/micrornas-as-biomarkers-for-psychiatric-disorders-with-a-focus-on-autism-spectrum-disorder-current-progress-in-genetic-association-studies-expression-profiling-and-translational-research
#2
REVIEW
Yubin Hu, Erik A Ehli, Dorret I Boomsma
MicroRNAs (miRNAs) are a group of small noncoding RNA molecules, 18-25 nucleotides in length, which can negatively regulate gene expression at the post-transcriptional level by binding to messenger RNAs. About half of all identified miRNAs in humans are expressed in the brain and display regulatory functions important for many biological processes related to the development of the central nervous system (CNS). Disruptions in miRNA biogenesis and miRNA-target interaction have been related to CNS diseases, including psychiatric disorders...
April 17, 2017: Autism Research: Official Journal of the International Society for Autism Research
https://www.readbyqxmd.com/read/28401046/functional-neuroanatomy-in-panic-disorder-status-quo-of-the-research
#3
Thomas Sobanski, Gerd Wagner
AIM: To provide an overview of the current research in the functional neuroanatomy of panic disorder. METHODS: Panic disorder (PD) is a frequent psychiatric disease. Gorman et al (1989; 2000) proposed a comprehensive neuroanatomical model of PD, which suggested that fear- and anxiety-related responses are mediated by a so-called "fear network" which is centered in the amygdala and includes the hippocampus, thalamus, hypothalamus, periaqueductal gray region, locus coeruleus and other brainstem sites...
March 22, 2017: World Journal of Psychiatry
https://www.readbyqxmd.com/read/28387722/translocator-protein-18-kda-tspo-positron-emission-tomography-pet-imaging-and-its-clinical-impact-in-neurodegenerative-diseases
#4
REVIEW
Anne-Claire Dupont, Bérenger Largeau, Maria Joao Santiago Ribeiro, Denis Guilloteau, Claire Tronel, Nicolas Arlicot
In vivo exploration of activated microglia in neurodegenerative diseases is achievable by Positron Emission Tomography (PET) imaging, using dedicated radiopharmaceuticals targeting the translocator protein-18 kDa (TSPO). In this review, we emphasized the major advances made over the last 20 years, thanks to TSPO PET imaging, to define the pathophysiological implication of microglia activation and neuroinflammation in neurodegenerative diseases, including Parkinson's disease, Huntington's disease, dementia, amyotrophic lateral sclerosis, multiple sclerosis, and also in psychiatric disorders...
April 7, 2017: International Journal of Molecular Sciences
https://www.readbyqxmd.com/read/28386521/micrornas-as-biomarkers-for-psychiatric-conditions-a-review-of-current-research
#5
REVIEW
Anoop Narahari, Mariyah Hussain, Venkatesh Sreeram
Neural-derived exosomes can be used as diagnostic markers to screen for various psychiatric conditions. These intravenously injected exosomes carry the potential to cross the blood brain barrier and deliver miRNA molecules specifically to neurons, microglia, and oligodendrocytes in the brain, resulting in specific gene knockdown. Here the authors review and discuss the current research on microRNA molecules and the therapeutic roles they may potentially play in treating depression, bipolar disorder, and schizophrenia...
January 2017: Innovations in Clinical Neuroscience
https://www.readbyqxmd.com/read/28385493/inflammation-and-internalizing-disorders-in-adolescents
#6
Cristiano Tschiedel Belem da Silva, Marianna de Abreu Costa, Flávio Kapczinski, Bianca Wollenhaupt de Aguiar, Giovanni Abrahão Salum, Gisele Gus Manfro
Serum inflammatory markers have been studied in adults with anxiety and depression, but little is known about cytokine levels in young adolescents with emotional disorders. The objective of this study is to compare serum levels of interleukin-6 (IL-6) and interleukin-10 (IL-10) between adolescents with internalizing disorders and adolescents from the same community without internalizing disorders. A total of 134 non-medicated subjects (n=76 with internalizing disorders) were recruited from a larger sample of 2457 individuals...
April 3, 2017: Progress in Neuro-psychopharmacology & Biological Psychiatry
https://www.readbyqxmd.com/read/28374419/the-acute-phase-mediator-serum-amyloid-a-is-associated-with-symptoms-of-depression-and-fatigue
#7
E Y Bryleva, S A Keaton, J Grit, Z Madaj, A Sauro-Nagendra, L Smart, S Halstead, E Achtyes, L Brundin
OBJECTIVE: Establish whether inflammatory biomarkers-serum amyloid A (SAA), C-reactive protein (CRP), interleukin-6 (IL-6), and tumor necrosis factor-α (TNF-α)-are related to key symptoms of depression, including anxiety and fatigue, in a cross-sectional, out-patient setting to identify biomarkers that reflect psychiatric symptomatology in a naturalistic, real-life population. METHODS: We measured SAA, CRP, IL-6, and TNF-α in plasma samples from 89 adult psychiatric out-patients by multiplex, high-sensitivity electrochemiluminescent assays...
May 2017: Acta Psychiatrica Scandinavica
https://www.readbyqxmd.com/read/28371745/homocysteine-as-a-peripheral-biomarker-in-bipolar-disorder-a-meta-analysis
#8
E Salagre, A F Vizuete, M Leite, D J Brownstein, A McGuinness, F Jacka, S Dodd, B Stubbs, C A Köhler, E Vieta, A F Carvalho, M Berk, B S Fernandes
BACKGROUND: Bipolar disorder (BD) is a psychiatric disorder with an uncertain aetiology. Recently, special attention has been given to homocysteine (Hcy), as it has been suggested that alterations in 1-carbon metabolism might be implicated in diverse psychiatric disorders. However, there is uncertainty regarding possible alterations in peripheral Hcy levels in BD. METHODS: This study comprises a meta-analysis comparing serum and plasma Hcy levels in persons with BD and healthy controls...
March 1, 2017: European Psychiatry: the Journal of the Association of European Psychiatrists
https://www.readbyqxmd.com/read/28353256/proteomic-approaches-to-enable-point-of-care-testing-and-personalized-medicine-for-psychiatric-disorders
#9
Francesca L Guest, Paul C Guest
This chapter describes how innovations that are driven by proteomic biomarker techniques can facilitate earlier and better treatment of patients who suffer from psychiatric disorders. The application of new micro-fluidic devices along with miniaturized biosensors and transducers will enable the development of handheld point-of-care testing instruments which can analyse a drop of a blood within the time span of a single visit to the doctor's office. It is anticipated that these approaches will incorporate both biochemical and clinical information, resulting in unique profiles for each test subject...
2017: Advances in Experimental Medicine and Biology
https://www.readbyqxmd.com/read/28353251/proteomic-profiling-of-the-pituitary-gland-in-studies-of-psychiatric-disorders
#10
Divya Krishnamurthy, Hassan Rahmoune, Paul C Guest
Psychiatric disorders have been associated with perturbations of the hypothalamic-pituitary-adrenal axis. Therefore, proteomic studies of the pituitary gland have the potential to provide new insights into the underlying pathways affected in these conditions as well as identify new biomarkers or targets for use in developing improved medications. This chapter describes a protocol for preparation of pituitary protein extracts followed by characterization of the pituitary proteome by label-free liquid chromatography-tandem mass spectrometry in expression mode (LC-MS(E))...
2017: Advances in Experimental Medicine and Biology
https://www.readbyqxmd.com/read/28353239/application-of-itraq-shotgun-proteomics-for-measurement-of-brain-proteins-in-studies-of-psychiatric-disorders
#11
Erika Velásquez Núñez, Paul C Guest, Daniel Martins-de-Souza, Gilberto Barbosa Domont, Fábio César Sousa Nogueira
Shotgun proteomics has been used successfully for more than two decades for measurement of proteins from diverse biological systems. This has led to new insights and identification of potential biomarkers and drug targets for numerous medical conditions. The advent of mass-labeling approaches such as isobaric tagging for relative and absolute quantitation (iTRAQ) has allowed multiplexing of samples to improve the accuracy and throughput of experiments and the reduction of costs. Here, we describe a detailed iTRAQ mass spectrometry protocol for simultaneous analysis of four proteomes from postmortem brain tissue extracts...
2017: Advances in Experimental Medicine and Biology
https://www.readbyqxmd.com/read/28353238/a-selected-reaction-monitoring-mass-spectrometry-protocol-for-validation-of-proteomic-biomarker-candidates-in-studies-of-psychiatric-disorders
#12
Guilherme Reis-de-Oliveira, Sheila Garcia, Paul C Guest, Juliana S Cassoli, Daniel Martins-de-Souza
Most biomarker candidates arising from proteomic studies of psychiatric disorders have not progressed for use in clinical studies due to insufficient validation steps. Here we describe a selective reaction monitoring mass spectrometry (SRM-MS) approach that could be used as a follow-up validation tool of proteins identified in blood serum or plasma. This protocol specifically covers the stages of peptide selection and optimization. The increasing application of SRM-MS should enable fast, sensitive, and robust methods with the potential for use in clinical studies involving sampling of serum or plasma...
2017: Advances in Experimental Medicine and Biology
https://www.readbyqxmd.com/read/28353236/identifying-biomarker-candidates-in-the-blood-plasma-or-serum-proteome
#13
Sheila Garcia, Licia C Silva-Costa, Guilherme Reis-de-Oliveira, Paul C Guest, Paulo A Baldasso, Juliana S Cassoli, Daniel Martins-de-Souza
Brain disorders are among the most complex and difficult to understand of human disorders in terms of pathophysiology and etiology. Differently from other human diseases such as cancer, which uses biomarkers in clinical practice, there are no prognostic and diagnostic biomarkers available for psychiatric disorders. Those associated with the likelihood of a successful medication are also not existent, impairing treatment strategies. Proteomics is a suitable tool for identifying such biomarkers to be validated and further implemented in the clinic...
2017: Advances in Experimental Medicine and Biology
https://www.readbyqxmd.com/read/28353231/multiplex-immunoassay-profiling-of-serum-in-psychiatric-disorders
#14
Laurie Stephen, Emanuel Schwarz, Paul C Guest
Multiplex immunoassays allow for the rapid profiling of biomarker proteins in biological fluids, using less sample and labour than in single immunoassays. This chapter details the methods to develop and manufacture a 5-plex immunoassay for the Luminex® platform. Although assay development is not included here, the same methods can be used to covalently couple antibodies to the Luminex beads and to label antibodies for the screening of sandwich pairs, if needed. An example will be given for the analysis of five hormones (glucagon-like peptide 1, growth hormone, insulin, leptin and thyroid-stimulating hormone) in serum samples from schizophrenia patients and controls...
2017: Advances in Experimental Medicine and Biology
https://www.readbyqxmd.com/read/28353230/blood-sampling-and-preparation-procedures-for-proteomic-biomarker-studies-of-psychiatric-disorders
#15
Paul C Guest, Hassan Rahmoune
A major challenge in proteomic biomarker discovery and validation for psychiatric diseases is the inherent biological complexity underlying these conditions. There are also many technical issues which hinder this process such as the lack of standardization in sampling, processing and storage of bio-samples in preclinical and clinical settings. This chapter describes a reproducible procedure for sampling blood serum and plasma that is specifically designed for maximizing data quality output in two-dimensional gel electrophoresis, multiplex immunoassay and mass spectrometry profiling studies...
2017: Advances in Experimental Medicine and Biology
https://www.readbyqxmd.com/read/28353228/lc-ms-e-for-qualitative-and-quantitative-proteomic-studies-of-psychiatric-disorders
#16
Mariana Fioramonte, Paul C Guest, Daniel Martins-de-Souza
This chapter describes the advantages and disadvantages of label-free liquid chromatography mass spectrometry in data-independent analysis mode (LC-MS(E)) in the identification of disease biomarkers in studies of psychiatric disorders. Along with the description of the technology, we discuss some of the most significant findings from various studies of post-mortem brain and neuroendocrine tissues from psychiatric disorder patients compared with controls. In addition, we describe some of the needs and challenges of performing these analyses in body fluids and peripheral tissues from living patients in order to increase translation of the findings into the clinical environment...
2017: Advances in Experimental Medicine and Biology
https://www.readbyqxmd.com/read/28353227/connecting-brain-proteomics-with-behavioural-neuroscience-in-translational-animal-models-of-neuropsychiatric-disorders
#17
Zoltán Sarnyai, Paul C Guest
Modelling psychiatric disorders in animals has been hindered by several challenges related to our poor understanding of the disease causes. This chapter describes recent advances in translational research which may lead to animal models and relevant proteomic biomarkers that can be informative about disease mechanisms and potential new therapeutic targets. The review focuses on the behavioural and molecular correlates in models of schizophrenia and major depressive disorder, as guided by recently established Research Domain Criteria (RDoC)...
2017: Advances in Experimental Medicine and Biology
https://www.readbyqxmd.com/read/28353225/application-of-proteomic-approaches-to-accelerate-drug-development-for-psychiatric-disorders
#18
Hassan Rahmoune, Daniel Martins-de-Souza, Paul C Guest
Proteomic-based biomarkers are now an integral part of the drug development process. This chapter covers the role of proteomic biomarker tests as useful tools for improving preclinical research and clinical development. One medical area that has been lagging behind this process is the study of psychiatric disorders, and this is most likely due to the complexity of these diseases. The potential of incorporating biomarkers in the clinical pipeline to improve decision-making, accelerate drug development, improve translation and reduce development costs is also discussed, with a focus on psychiatric diseases like schizophrenia...
2017: Advances in Experimental Medicine and Biology
https://www.readbyqxmd.com/read/28353223/multiplexing-biomarker-methods-proteomics-and-considerations-for-alzheimer-s-disease
#19
Renã A S Robinson, Bushra Amin, Paul C Guest
Biomarker research for Alzheimer's disease (AD) has been growing rapidly over recent years especially as the number of persons affected by this disease is nearing approximately 46 million worldwide. Single biomarker assays are challenging to establish since AD is multifactorial and complex. In addition to the classic signs of diminished cognition and memory, AD patients can also exhibit symptoms which may be confused with some psychiatric disorders, such as depression. No molecular biomarkers have been established or translated into clinical tools although recent efforts have resulted in addition of molecular biomarker profiles to the National Institute of Neurological and Communicative Disorders and Stroke and Alzheimer's Disease and Related Disorders Association criteria for research purposes...
2017: Advances in Experimental Medicine and Biology
https://www.readbyqxmd.com/read/28353222/application-of-proteomic-techniques-for-improved-stratification-and-treatment-of-schizophrenia-patients
#20
Johann Steiner, Paul C Guest, Daniel Martins-de-Souza
For major psychiatric disorders such as schizophrenia, there have been shortcomings in the translation of scientific findings into new treatments and this has led to diminished interest for large pharmaceutical companies. This chapter describes how incorporation of proteomic approaches into the clinical pipeline can lead to identification and implementation of biomarker tests for improved patient characterization, prediction of treatment response and monitoring treatment effects to help revitalize efforts in this important area...
2017: Advances in Experimental Medicine and Biology
keyword
keyword
76186
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"